Pharmacy and Wellness Review
Volume 3

Issue 2

Article 2

July 2012

Lysteda® for Heavy Menstrual Bleeding
Erica B. Schoenberger
Ohio Northern University

Todd A. Tucker Jr.
Ohio Northern University

Justin W. Steele
Ohio Northern University

Amanda Meyer
Ohio Northern University

Sandra L. Hrometz
Ohio Northern University

Follow this and additional works at: https://digitalcommons.onu.edu/paw_review
Part of the Medical Pharmacology Commons, Pharmaceutics and Drug Design Commons, and the
Women's Health Commons
This Article is brought to you for free and open access by
the ONU Journals and Publications at
DigitalCommons@ONU. It has been accepted for
inclusion in Pharmacy and Wellness Review by an
authorized editor of DigitalCommons@ONU. For more
information, please contact digitalcommons@onu.edu.

Endocrine

Lysteda® for Heavy Menstrual Bleeding
Erica 8. Schoenberger, fifth-year pharmacy student from Upper Sandusky, Ohio; Todd A. Tucker Jr., fourth-year pharmacy
student from Barnesville, Ohio; Justin W. Steele, fourth-year pharmacy student from Canton, Ohio; Amanda Meyer, fifthyear pharmacy student from Dublin, Ohio; Sandra L. Hrometz, BS Ph '94, R.Ph., Ph.D., professor of pharmacology

This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.
ACPE Universal Activity Number (UAN): 0048-0000-12-031-HOl-P

Objectives
1.
2.
3.
4.

Describe the mechanism of action of Lysteda®.
Compare and contrast treatment options for heavy
menstrual bleeding.
List the side effects and warnings associated with
Lysteda®.
Explain important patient counseling information.

Abstract
Lysteda®, a novel formulation of tranexamic acid, is an antifibrinolytic medication recently approved by the Food and
Drug Administration (FDA) for the treatment of heavy
menstrual bleeding. Tranexamic acid has been shown to
significantly reduce menstrual blood loss while simultaneously allowing a woman to safely become pregnant. The
major advantage of Lysteda® (an oral modified-release
formulation of tranexamic acid) compared to oral immediate
-release tranexamic acid, is the decreased occurrence of
gastrointestinal side effects. As there are no therapeutic
equivalents to Lysteda® for heavy menstrual bleeding, it is
important for pharmacists to be able to counsel patients
appropriately on the specific dosing regimen and side effects
of this new product.

Introduction
During normal menstruation women lose approximately 3545 mL of blood every 21 to 35 days. The amount of blood lost
with each menstrual cycle varies between women and
throughout an individual's life. 1 The American Congress of
Obstetricians and Gynecologists define menorrhagia, or
heavy menstrual bleeding (HMB), as the "loss of 80 mL or
more of blood per cycle or bleeding that lasts for more than
seven days," however it can also be diagnosed based on a
patient's perception of excessive bleeding and interference
with physical, social, and/or emotional quality of life.z.3 Lysteda® (Ferring Pharmaceuticals Inc., Parsippany, N.J.) is the
only non-hormonal medication approved to treat cyclic HMB
in the United States. 4 Immediate-release tranexamic acid
(TA) has been utilized in Europe, Canada, Asia and Australia
for over 30 years to decrease menstrual blood loss, and it is
even available over-the-counter in select countries.4.s The
antifibrinolytic, Lysteda®, made its debut on the U.S. market
in July 2010. With approximately 27 percent of women ex110

periencing a decreased quality of life due to HMB, Lysteda®
has the potential to greatly impact a significant number of
women.4 To differentiate the modified- and immediaterelease forms of tranexamic acid, we will refer to the modified-release form as Lysteda® and the immediate-release
form as TA throughout the remainder of this article.

Pathophysiology
Fibrinolysis, or dissolution of a clot, begins when endothelial
cells release tissue plasminogen activator (tPA).6 TPA facilitates the binding of plasminogen to lysine binding sites on
fibrin, resulting in the conversion of plasminogen to plasmin.
Plasmin is ultimately responsible for degrading clots, and in
the uterus, the result is menstrual bleeding. Regulatory
mechanisms usually control fibrinolysis, but when they fail,
excessive uterine fibrinolysis may occur and lead to HMB.
Tranexamic acid, a synthetic lysine analog, decreases menstrual blood loss by reversibly blocking the lysine binding
site on plasminogen, preventing the formation of plasmin
and subsequent fibrinolysis. HMB may be due to a specific
biological cause such as uterine polyps, fibroids, endometriosis, von Willebrand's disease or hemophilia; however, half of
all women with HMB suffer from idiopathic HMB. Idiopathic
HMB is attributed to elevated levels of endometrial tPA and
plasmin compared to women with normal bleeding, making
antifibrinolytic medications such as Lysteda® an ideal treatment option.

Review of Other Treatment Options for HMB
Lysteda® is a unique and effective way of treating menorrhagia. However, because this non-hormonal treatment
option was recently FDA approved and is the first of its kind,
many health care professionals may not feel comfortable
counseling patients on this new medication. With Lysteda ®
costing nearly $170 for a five day supply of 30 tablets, physicians and patients must consider the price of Lysteda® compared to more traditional medications.7 The unique qualities
of Lysteda® may be worth the price in patients who refuse,
have failed or cannot tolerate traditional therapies.
One of the first questions considered upon treating menorrhagia is whether the woman wishes to preserve long-term
fertility. If she does not wish to preserve long-term fertility,
she may consider one of two primary surgical procedures:
hysterectomy or endometrial ablation.8 Hysterectomies are
becoming much less common as second -generation endometrial ablation becomes more advanced. 9 These surgical
procedures are very effective for menorrhagia, but are becoming less practical as medications become more effective,
while providing the opportunity for continued fertility.
If a woman wishes to preserve her fertility long term, hormonal therapy (including hormonal contraceptives or cyclic

Lysteda® for Heavy Menstrual Bleeding

progesterone) and non-steroidal anti-inflammatory drugs
(NSAIDs) are traditional options.
It has been long established that the best nonsurgical treatment option for HMB is the levonorgestrel-containing intrauterine device (LNG-IUD).a.10.11 It ranks higher than all other
medical treatments when considering effectiveness, side effects and length of treatment. 11 The LNG-IUD is the first-line
therapy in treating menorrhagia as outlined by Britain's National Institute for Health and Clinical Excellence (NICE)
guidelines for HMB released in January of 2007. 10 Women
must be fitted for the IUD by a doctor or specially trained
nurse and, after insertion, the IUD should be replaced every
five years. This system works by releasing 20 mcg of
levonorgestrel, a synthetic progesterone, every 24 hours.1
This product suppresses endometrial growth, which causes
endometrial glands to atrophy.a Some irregular spotting may
occur within the first few months and approximately 25 percent of users develop amenorrhea, but overall patient satisfaction is high.1,13 There is a small chance of uterine perforation at the time of placement. Common side effects include
headache, breast tenderness and acne.12,13
Combined hormonal contraceptives (CHCs) reduce menstrual blood loss by approximately 40 percent.a.9 On March
14, 2012, the four-phase oral contraceptive Natazia®
(estradiol valerate and estradiol valerate/dienogest), became
the first and only FDA approved CHC for the treatment of
HMB.14 CHCs are administered in either a cyclic or continuous manner and, like LNG-IUDs, they prevent proliferation of
the endometrium.a.9,12 Continuous administration products
(meaning no inert or hormone-free interval) may improve
bleeding patterns and other symptoms associated with menstruation, but the patient may also experience some breakthrough bleeding.a.9 Although these drugs generally do not
appear to pose a risk with long-term use, it should be noted
that they are not recommended in some patient populations,
such as smokers older than 35 years, as they increase the risk
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of venous thromboembolism, stroke or heart attack.ta.10 Common side effects associated with CH Cs include headache, mood
changes, nausea, fluid retention and breast tenderness. 12
Like the other hormonal options, cyclically administered oral
progestins prevent the proliferation of the endometrium and
may cause amenorrhea, which may be a desired effect in patients with HMB. 9·13 Although the cyclically administered oral
progestins are not FDA-labeled contraceptives, they may affect a woman's ability to become pregnant. Progestins may
result in weight gain, bloating, breast tenderness, headaches,
acne and, possibly, depression.13
Many women will initially attempt to treat heavy and painful
periods on their own, making NSAIDS a popular choice.
NSAIDs are the most common medications used for HMB in
women who do not want hormone therapy or wish to become pregnant. By inhibiting the formation of Prostaglandins
E and 12, which appear to be elevated during menstruation
and endometrial shedding, NSAIDs are able to reduce blood
flow.1 Another benefit of NSAIDs is the additional analgesia
properties they provide. Because NSAIDs are only taken during menstruation, the gastrointestinal side effects commonly
associated with long-term NSAID use are of little concern.
Clinical efficacy between different NSAIDs appears to be
similar.a According to the NICE guidelines, NSAIDs are preferred over TA in patients experiencing HMB with dysmennorhea, due to the cost and analgesic effects. 12 However,
Lysteda® is an option for HMB in women wishing to avoid
hormonal therapy and either cannot tolerate or are refractory to NSAID therapy.
Efficacy ofTranexamic Acid and Clinical Trials
In regards to efficacy, clinical trials performed by Lukes, et al.
and Freeman, et al. have demonstrated favorable outcomes
in terms of the ability of Lysteda® to both reduce menstrual
blood loss and improve quality of life in women suffering
from HMB.3,1s In 2010, a double-blind, randomized con-

Table 1. Treatment Options for HMB.3,10,12
SURGICAL
Decrease in
Bleeding(%)

Procedure
Hysterectomy

100

Endometrial Ablation

80-94

Eliminate
long-term
fertility
Yes
Yes

Contraceptive Action
---------------

PHARMACOLOGICAL
NICE Guidelines

Decrease in
Bleeding(%)

LNG-IUD

1st Line

79-97

Eliminate
long-term
fertility
No

Oral Progestin

3rd Line

87

No

Possible

CO Cs

2nd Line

20-50

No

Yes

GnRH analogues
NSAIDs

Other

>90

2nd Line

20-50

No
No

No
No

Tranexamic Acid

2nd Line

20-60

No

No

N/A

40

No

No

Type

Hormonal

Nonhormonal

Class

Lysteda®

Contraceptive Action
Yes
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trolled trial conducted by Lukes, et al. evaluated the effects of
TA in adult women with HMB.3 Women free of uterine abnormalities experiencing an average blood loss of at least 80 mL
per menstrual cycle were randomized to receive either 3.9 g/
day TA or placebo. Participating women received treatment
at the onset of menses for up to five days each menstrual cycle and were studied over the course of six cycles. Menstrual
blood was collected and measured to determine a mean reduction in blood loss. Furthermore, improvements in quality
of life were assessed based on participant responses to the
Menorrhagia Impact Questionnaire (MIQ), a six-question
questionnaire designed to evaluate HMB-related limitations
on daily activities and detect patient perceived changes in
blood loss.
At the conclusion of the trial, a significant reduction in menstrual blood loss in the modified intent-to-treat population
(-69.6 mL; -40.4 percent) as compared to placebo (-12.6 mL;
-8.2 percent; p<0.001) was found. Furthermore, researchers
found a significant reduction in MIQ scores on limitation in
social, leisure and physical activities in the TA group compared to placebo (p<0.001). However, it should be noted that
the study was five participants short of meeting power, as
there were only 115 participants in the modified intent-totreat receiving TA instead of the calculated 120 participants.
Similar results were found in an analogous study performed
by Freeman, et al. in which women with an average menstrual blood loss of at least 80 mL per cycle were randomized
to receive either 3.9 g/day TA or placebo.ls By the conclusion
of the trial, the modified intent-to-treat population consisted
of 112 subjects in the treatment group and 67 subjects in the
placebo group, which was sufficient to meet power. In terms
of results, experimenters found a 38.6 percent (-65.3 mL)
reduction from baseline in menstrual blood loss in participants receiving TA compared to placebo (-1.9 percent; -3.0
mL; p<0.0001).

Long-Term Safety and Health-Related Quality of Life
The long-term safety and health-related quality of life
(HRQoL) of Lysteda® was examined in a multi-center, openlabel trial lasting 27 months (HRQoL evaluated during the
first 15 months) and included 62 sites within the United
States.16 Patients aged 18 to 49 years old with a history of
HMB were diagnosed with HMB based on the medical judgment of study investigators. The intent-to-treat population
included 723 patients, with 239 patients completing all 27
months. The most common reasons for withdrawing from
the study were not related to the treatment (29 percent
failed to return and 22 percent had unrelated requests).
Eleven percent of patients reported treatment-emergent adverse effects (TEAEs) that the investigators considered related to Lysteda®. Gastrointestinal side effects were reported
by 102 patients and no patients developed a venous thromboembolism (VTE) or pulmonary embolism (PE) during the
study. Serious TEAEs were reported by 28 women and two
women had life-threatening TEAEs, however the two events
were related to other health issues and not Lysteda®. Fourteen women became pregnant and no fetal abnormalities

reported eye issues, but only one patient had to withdraw
due to severe blurred vision, which completely returned to
normal upon discontinuation of Lysteda®.
HRQoL was measured using the Short Form 36 Health Survey (SF-36), a general health assessment tool, and the Ruta
Menorrhagia Questionnaire (RMQ), a disease specific tool.
Both showed statistically and clinically significant improvements mentally, emotionally and physically starting with the
first cycle of treatment and persisting throughout treatment.
This study had a few major drawbacks. First of all, the investigators subjectively determined causality between the
adverse effects and medication use. Secondly, they decided
the significance of reported adverse events, resulting in
possibly biased results. Finally, they did not report the
number of patients included in the 15 month HRQoL portion
of the study. Overall, this study concluded that gastrointestinal issues with Lysteda® occur at rates lower than reported
with TA and demonstrated no increased risk of developing
thromboembolism due to Lysteda® use, however there is a
small risk of serious ophthalmic issues.

Pharmacist Information and Patient Counseling
The main advantage of Lysteda®over TA is a decreased occurrence of gastrointestinal side effects such as nausea, vomiting, diarrhea and dyspepsia, resulting in greater tolerability
and patient compliance.16 The most common side effects reported with Lysteda® are those associated with menstruation, including menstrual discomfort, headache and back
pain.17 However, these side effects may be reduced with concurrent use of acetaminophen, ibuprofen or naproxen.17 The
most serious adverse effects possible with Lysteda® are
thromboembolisms and ocular disturbances. To avoid an
excessive risk of thrombosis, it is contraindicated in patients
with active, history of, or other risk factors for thromboembolism.10 Additionally, Lysteda® should not be used concomitantly with CH Cs or hormone replacement therapy.17 It is also
important to warn patients of possible visual changes which
will reverse upon discontinuation of the medication.
The recommended dosage of Lysteda® is 1300 mg (two 650
mg tablets) taken three times per day, with doses separated
by six hours.4,17 It can be taken with or without food.18 Dose
adjustments are required in patients with a serum creatinine
greater than 1.4 mg/dL (Table 2).18 Women should be instructed to begin taking Lysteda®at the onset of menses, and
continue use for a maximum of five days throughout menstruation. Since Lysteda® is only intended to be taken during
menstruation, pharmacists should remind patients not to
take it continuously throughout the month, as is common
with other treatments.
Finally, since patients may confuse Lysteda® with more traditional hormonal treatments for HMB, pharmacists should
explain that Lysteda® is a non-hormonal medication and has
no effect on fertility.4 Therefore, women may become pregnant and should be instructed to use barrier forms of contraception if necessary. Other counseling points include educat-
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Tab e2. Rena ID ose Ad"JUStments or Lyste d a @1 8
Serum Creatinine (mg/dL)

Dosing

~1.4

1300 mgTID

1.5 - 2.8

1300mgBID

2.9 - 5.7

1300 mg daily

~

5.8

650 mg daily

ing women on ways to manage premenstrual symptoms,
such as drinking plenty of water, getting adequate rest and
avoiding excessive salt and caffeine intake.
Conclusion
Heavy menstrual bleeding is a troublesome condition that
interferes with the lives of approximately 27 percent of
women. To date, there are several treatment options available to reduce bleeding, such as hormones, NSAIDS, Lysteda®
and surgery in severe cases. The non-hormonal Lysteda®
may help women effectively reduce menstrual bleeding without interfering with the ability to conceive. With Lysteda®,
women can expect to see an approximate 40 percent reduction in bleeding while experiencing only the mild side effects
associated with menstruation. Furthermore, Lysteda® has
demonstrated a favorable safety profile and has not been
associated with any serious adverse events. Since it was only
recently introduced to the U.S. market in July 2010, much of
the medical community remains unfamiliar with Lysteda®;
however, it is an additional, effective, non-hormonal treatment option for women suffering from HMB.
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Assessment Questions
1. Idiopathic heavy menstrual bleeding (HMB) is due to:
a. Excessive fibrin
b. Reduced lysine
c. Intrauterine devices (IUDs)
d. Elevated endometrial tPA and plasmin
2.

3.

Lysteda® reduces menstrual blood loss by:
a. Blocking lysine binding sites on plasminogen
b. Preventing synthesis oflysine
c. Increasing plasmin levels
d. Reducing endometrial tPA
Lysteda can treat HMB caused by:
a. Idiopathic causes
b. Endometriosis
c. von Willebrand's disease
d. Aand B
e. Band C

9.

10. Lysteda® can safely be taken concomitantly with which
medication(s)?
a. Advil®
b. Lo Loestrin Fe®
c. Premarin®
d. Band C
e. All of the above

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 05/08/ 15.

4. The most effective non-surgical treatment for HMB is:

a. Natazia®
b. Levonorgestrel-containing intrauterine
device (LNG-IUD)
c. Lysteda®
d. Ibuprofen

5.

FDA approved treatment options for HMB include:
a. Lysteda®
b. Natazia®
c. Advil®
d. Aand B
e. All of the above

What is the recommended dose of Lysteda® in a young,
healthy female?
a. 650 mg daily
b. 1300 mg daily for 21 days
c. 1300 mg TIO for a maximum of 5 days
d. 1300 mg as needed for heavy menstruation

To receive continuing education credit for this program, you
must answer the above questions and fill out the evaluation
form. Please visit www.onu.edu/pharmacy to enter the required information. Please allow two to three weeks for
electronic distribution of your continuing education certificate, which will be sent to your valid email address in PDF
format.

6. Lysteda reduced menstrual blood flow by approximately__ .
a. 20%
b. 40%
c. 60%
d. 80%
7. What is the major advantage of Lysteda® over tranexamic
acid?
a. Increased effectiveness
b. Reduced side effects
c. Easier administration
d. Reduced menstrual cramping
8.
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What serious side effect(s) is a concern with Lysteda®?
a. Amenorrhea
b. Ophthalmic issues
c. Nausea and vomiting
d. Aand C
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Describe the mechanism of action of Lysteda®.
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Compare and contrast treatment options for heavy menstrual
bleeding.

1

2

3

4

5

List the side effects and warnings associated with Lysteda®.

1

2

3

4

5

Explain important patient counseling information.
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4
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